Faron Pharmaceuticals Oy (LSE:FARN)

Half Year 2026 Faron Pharmaceuticals Oy Earnings Call Transcript

Aug 26, 2026 / 12:00 PM GMT

Release Date Price: £0.4 (-2.44%)

Transcript

Key Points

Positve

Faron Pharmaceuticals Oy (FRA:4FR) reported a 45% complete remission rate in frontline high-risk MDS, significantly higher than the historical 16-20% seen with standard azacitidine.
The company has a unique first-in-class anti-CLEVR-1 antibody, bexmarilimab, which not only kills cancer cells but also promotes healthy blood cell production, offering a differentiated safety profile.
Faron Pharmaceuticals Oy (FRA:4FR) successfully completed a €40 million rights issue, strengthening its cash position to €32 million and funding operations through the Phase IIb readout in 2027.
The company has secured regulatory approvals for multiple trials, including BLACE in checkpoint refractory lung and melanoma and BEXAR in soft tissue sarcoma, expanding its pipeline.
Faron Pharmaceuticals Oy (FRA:4FR) has dosed nearly 300 patients with bexmarilimab, demonstrating a robust and consistent safety profile with no surprises.
The company is well-positioned in the high-risk MDS landscape, with a leading disease-modifying agent as competitors' targets like CD47 and BCL2 have failed.
Faron Pharmaceuticals Oy (FRA:4FR) has partnered with Parexel, a world-leading CRO, to deliver the Phase IIb trial efficiently, with a risk-sharing agreement that caps costs.
The company's cash runway does not assume additional financing, and it has a disciplined cost management approach, with operating loss broadly in line with the prior year.
Faron Pharmaceuticals Oy (FRA:4FR) expects to report mature survival data from frontline and last-line settings, with last-line survival potentially doubling the historical median of 5-6 months.
The company has strengthened its team with key hires, including a Chief Technical Officer and a board member with business development experience, enhancing execution capabilities.

Negative

Faron Pharmaceuticals Oy (FRA:4FR) has not yet started the Phase IIb BEXERA trial, with first patient enrollment expected later this year, and the readout is not until late 2027, creating a long wait for catalysts.
The company's cash runway is only until Q4 2027, and it does not include potential costs from faster enrollment or unplanned IIT support, which could strain finances.
The FINPROOF study in breast cancer will not proceed, requiring a standalone study, and the company is focusing resources on MDS, potentially limiting pipeline diversification.
The Phase IIb trial has no interim analysis, so investors must wait for the final CR readout to determine go/no-go decisions, increasing uncertainty.
The company's success depends on achieving at least a 10% improvement in CR rate over azacitidine, which is not guaranteed despite promising Phase I/II data.
Faron Pharmaceuticals Oy (FRA:4FR) has a history of operating losses, and the operating loss of $11.1 million in H1 2026 indicates continued cash burn.
The company faces intense competition in high-risk MDS, with many pharma companies developing early-stage agents, though some targets have failed.
The rights issue resulted in dilution for existing shareholders, and the company has 227.8 million shares outstanding, which may pressure stock price.
The company's reliance on investigator-initiated trials (IITs) for solid tumor data may limit the robustness of evidence compared to sponsored trials.
There is no approved second-line therapy for high-risk MDS, and the company's last-line data, while promising, is based on open-label studies, which may not hold up in randomized trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FARN.L - Faron Pharmaceuticals Oy
Half Year 2026 Faron Pharmaceuticals Oy Earnings Call
Aug 26, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, everyone. Welcome to the Pharma Pharmaceuticals Half Year Report webcast.

Apologies for the technical issues in the beginning, but I think we're now up and running and happy to be here with you.

Next slide, please.

As a biotech classically, we will be making forward-looking statements, so our standard disclaimer.

Next slide, please.

For today's agenda, I will be taking you through the past key events and also the future outlook. Then our Chief Financial Officer Jurrien Tekkers will be presenting the actual financial results, followed by a Q&A session.

Next slide, please.

Okay, let's go to the key events of the first half.

Next slide

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.